HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Efficacy and Safety of the Selective Estrogen Receptor Down-Regulator "Fulvestrant" in Japanese Patients with Advanced, Recurrent, ER-Positive Postmenopausal Breast Cancer].

Abstract
Fulvestrant is a novel endocrine therapy for breast cancer that exerts both anti-estrogenic and down-regulatory effects by binding to and degrading estrogen receptors (ERs). In the present study, the safety and effectiveness of 500 mg fulvestrant in 69 patients with advanced, recurrent, ER-positive postmenopausal breast cancer were investigated retrospectively. Outcomes were favorable for fulvestrant. The objective response rate was 24.6%, the clinical benefit rate was 49.2%, the median progression-free survival (PFS) was 203 days, and the median overall survival was 794 days. PFS tended to be longer in patients without a history of previous treatment or visceral metastasis. The main adverse events included injection site reactions and hot flushes; however, the majority of these events were mild to moderate. The present findings suggest that, among Japanese patients with advanced, recurrent, ER-positive postmenopausal breast cancer, 500 mg fulvestrant is effective and safe in those without metastasis and a minimal history of receipt of previous treatment regimens.
AuthorsChiyomi Egawa, Masatsugu Okishiro, Yuichi Takatsuka
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 42 Issue 7 Pg. 811-5 (Jul 2015) ISSN: 0385-0684 [Print] Japan
PMID26197741 (Publication Type: Journal Article)
Chemical References
  • Estrogen Antagonists
  • Receptors, Estrogen
  • Fulvestrant
  • Estradiol
Topics
  • Aged
  • Aged, 80 and over
  • Asian People
  • Breast Neoplasms (chemistry, drug therapy)
  • Down-Regulation
  • Estradiol (adverse effects, analogs & derivatives, therapeutic use)
  • Estrogen Antagonists (adverse effects, therapeutic use)
  • Female
  • Fulvestrant
  • Humans
  • Middle Aged
  • Postmenopause
  • Receptors, Estrogen (analysis, antagonists & inhibitors)
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: